ATE557087T1 - Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz - Google Patents
Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanzInfo
- Publication number
- ATE557087T1 ATE557087T1 AT04787788T AT04787788T ATE557087T1 AT E557087 T1 ATE557087 T1 AT E557087T1 AT 04787788 T AT04787788 T AT 04787788T AT 04787788 T AT04787788 T AT 04787788T AT E557087 T1 ATE557087 T1 AT E557087T1
- Authority
- AT
- Austria
- Prior art keywords
- proliferative diseases
- sclerosis
- kit
- smad1
- stat3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003319538 | 2003-09-11 | ||
| PCT/JP2004/013124 WO2005026344A1 (ja) | 2003-09-11 | 2004-09-09 | 硬化をもたらす増殖性疾患の検出方法及びキット、硬化をもたらす増殖性疾患の予防及び/又は治療剤、ならびに硬化をもたらす増殖性疾患の予防及び/又は治療に有効な物質を同定する方法及びキット |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE557087T1 true ATE557087T1 (de) | 2012-05-15 |
Family
ID=34308570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04787788T ATE557087T1 (de) | 2003-09-11 | 2004-09-09 | Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7901874B2 (de) |
| EP (2) | EP1672062B1 (de) |
| JP (2) | JP4664815B2 (de) |
| KR (1) | KR101242260B1 (de) |
| CN (1) | CN1871347B (de) |
| AT (1) | ATE557087T1 (de) |
| WO (1) | WO2005026344A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7901874B2 (en) * | 2003-09-11 | 2011-03-08 | Hubit Genomix, Inc. | Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen |
| WO2008010556A1 (fr) | 2006-07-21 | 2008-01-24 | Chugai Seiyaku Kabushiki Kaisha | Médicament agissant contre une maladie rénale |
| CN101522194B (zh) * | 2006-08-04 | 2011-06-15 | 味之素株式会社 | 肾功能障碍预防/治疗剂 |
| BRPI1010655A2 (pt) | 2009-04-10 | 2019-09-03 | Qi Haiyan | novos agentes antienvelhecimento e métodos para identificá-los |
| WO2011119771A2 (en) * | 2010-03-23 | 2011-09-29 | The Salk Institute For Biological Studies | Methods and compositions for detecting protein modifications |
| JP5346360B2 (ja) | 2010-08-31 | 2013-11-20 | 株式会社マルハニチロ食品 | 塩分の吸収阻害作用をもつ血管保護剤 |
| JP5823031B2 (ja) | 2011-06-10 | 2015-11-25 | 日立化成株式会社 | 小胞捕捉デバイスおよびそれを用いるための方法 |
| WO2014055687A1 (en) | 2012-10-05 | 2014-04-10 | Hitachi Chemical Co., Ltd. | Urine exosome mrnas and methods of using same to detect diabetic nephropathy |
| WO2014182330A1 (en) | 2013-05-06 | 2014-11-13 | Hitachi Chemical Company Ltd | Devices and methods for capturing target molecules |
| US10266895B2 (en) | 2014-11-05 | 2019-04-23 | Hitachi Chemical Company Ltd. | Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease |
| EP3218521B1 (de) | 2014-11-12 | 2019-12-25 | Hitachi Chemical Co., Ltd. | Verfahren zur diagnose von organverletzung |
| US20170363612A1 (en) * | 2014-12-03 | 2017-12-21 | Wayne State University | Compositions and methods relating to proliferative disorders |
| JP6329501B2 (ja) * | 2015-03-11 | 2018-05-23 | アース環境サービス株式会社 | 昆虫の混入時期判定方法 |
| JP6841609B2 (ja) | 2015-07-10 | 2021-03-10 | 3スキャン インコーポレイテッド | 組織学的染色の空間的多重化 |
| DE112016003948T5 (de) | 2015-08-31 | 2018-05-09 | City Of Sapporo | Molekulare verfahren zum beurteilen einer urothelialen erkrankung |
| CN109891241B (zh) * | 2016-10-03 | 2022-12-06 | 秀比特生物技术公司 | 能够进行糖尿病性肾病的早期病情的特异性诊断的检查方法 |
| KR20250011598A (ko) * | 2023-07-14 | 2025-01-21 | 전남대학교산학협력단 | 암 진단을 위한 시료 처리 방법 및 이를 이용한 암 진단에 대한 정보 제공 방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US6780603B1 (en) * | 1995-07-21 | 2004-08-24 | Regents Of The University Of Minnesota | Analysis of alpha integrins for the diagnosis of diabetic nephropathy |
| US5908925A (en) * | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
| EP1146869A2 (de) * | 1999-01-27 | 2001-10-24 | University Of South Florida | Inhibierung der stat3 signaltransduktion für krebsbehandlung |
| US6013522A (en) * | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| EP1192174A4 (de) * | 1999-06-11 | 2002-08-28 | Univ New York State Res Found | Antagonisten von bmp- und tgf-beta signalwegen |
| US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
| AU2001251612A1 (en) * | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| JP4267864B2 (ja) | 2002-04-18 | 2009-05-27 | 古河電気工業株式会社 | フラットワイヤハーネスの長さ調節治具 |
| US20050272649A1 (en) * | 2002-08-28 | 2005-12-08 | Hruska Keith A | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US7560244B2 (en) * | 2003-06-04 | 2009-07-14 | Joslin Diabetes Center, Inc. | Method of evaluating a subject for risk or predisposition of reduced renal function over time |
| US7901874B2 (en) * | 2003-09-11 | 2011-03-08 | Hubit Genomix, Inc. | Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen |
| WO2008010556A1 (fr) * | 2006-07-21 | 2008-01-24 | Chugai Seiyaku Kabushiki Kaisha | Médicament agissant contre une maladie rénale |
| US8926710B2 (en) * | 2010-10-25 | 2015-01-06 | Warsaw Orthopedic, Inc. | Osteoinductive bone graft injectable cement |
-
2004
- 2004-09-09 US US10/571,511 patent/US7901874B2/en active Active
- 2004-09-09 CN CN2004800263069A patent/CN1871347B/zh not_active Expired - Lifetime
- 2004-09-09 AT AT04787788T patent/ATE557087T1/de active
- 2004-09-09 EP EP04787788A patent/EP1672062B1/de not_active Expired - Lifetime
- 2004-09-09 WO PCT/JP2004/013124 patent/WO2005026344A1/ja not_active Ceased
- 2004-09-09 KR KR1020067004858A patent/KR101242260B1/ko not_active Expired - Lifetime
- 2004-09-09 EP EP10010148A patent/EP2261331A1/de not_active Withdrawn
- 2004-09-09 JP JP2005513889A patent/JP4664815B2/ja not_active Expired - Lifetime
-
2009
- 2009-09-28 US US12/585,882 patent/US9359645B2/en not_active Expired - Fee Related
-
2010
- 2010-09-29 JP JP2010218011A patent/JP5199322B2/ja not_active Expired - Lifetime
-
2016
- 2016-05-04 US US15/146,515 patent/US20160333412A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080025967A1 (en) | 2008-01-31 |
| EP1672062A4 (de) | 2007-10-31 |
| CN1871347B (zh) | 2011-05-25 |
| WO2005026344A1 (ja) | 2005-03-24 |
| KR101242260B1 (ko) | 2013-03-13 |
| CN1871347A (zh) | 2006-11-29 |
| EP1672062A1 (de) | 2006-06-21 |
| HK1097880A1 (en) | 2007-07-06 |
| JPWO2005026344A1 (ja) | 2007-11-08 |
| US9359645B2 (en) | 2016-06-07 |
| EP1672062B1 (de) | 2012-05-09 |
| EP2261331A1 (de) | 2010-12-15 |
| JP4664815B2 (ja) | 2011-04-06 |
| US20160333412A1 (en) | 2016-11-17 |
| KR20070026303A (ko) | 2007-03-08 |
| US7901874B2 (en) | 2011-03-08 |
| JP5199322B2 (ja) | 2013-05-15 |
| JP2011050383A (ja) | 2011-03-17 |
| US20100135988A1 (en) | 2010-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE557087T1 (de) | Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz | |
| CY1110503T1 (el) | Πενταμιδινη για θεραπεια καρκινου | |
| DE60335921D1 (de) | Thrombusdetektor, vorrichtung zur behandlung von thromben und verfahren dafür | |
| DE60039824D1 (de) | Vorrichtung zur Behandlung von biologischen Geweben mittels Elektrizität oder Medikamenten | |
| EP1123130A4 (de) | Vorrichtung und verfahren zur diagnose und therapie von elektrophysiologischen krankheiten | |
| ATE526029T1 (de) | Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung | |
| ATE288675T1 (de) | Verfahren und vorrichtung zum schwenken der abteiler von mehrteiligen landwirtschaftlichen erntemaschinen | |
| DE602004017283D1 (de) | Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| EP1635801A4 (de) | Verfahren zur behandlung und prävention von herzarrhythmie | |
| DE69504949T3 (de) | Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs | |
| DE602004026405D1 (de) | Formulierung und verfahren zur behandlung von thrombocythämie | |
| ATE173620T1 (de) | Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| DE60315575D1 (de) | Verfahren und Vorrichtung zur Untersuchung von Oberflächen | |
| EP1684735A4 (de) | Verbindungen und verfahren zur behandlung und prävention von belastungsinduzierten herzarrhythmien | |
| DE60128427D1 (de) | Verfahren und Einrichtungen zur elekrochemischen Behandlung eines Artikels | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| ATE393243T1 (de) | Diagnostisches verfahren der mastozytose | |
| EP1363528A4 (de) | Verfahren zur diagnose und behandlung von herzerkrankungen | |
| DE60103939D1 (de) | Gehärteter Kautschuk und Verfahren zur Behandlung von gehärtetem Kautschuk | |
| WO2002020003A3 (en) | Use of carp inhibitors for the treatment of heart diseases | |
| DE602004004708D1 (de) | Vorrichtung und Verfahren zur Bestimmung von Bakterien | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| ATE390435T1 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie |